Pancreatic Cancer

Zoldonrasib was well tolerated and associated with manageable AEs and preliminary antitumor activity in patients with KRAS G12D–mutated PDAC.

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

An orphan medicinal product designation was granted to elraglusib by the EMA for patients with advanced pancreatic ductal adenocarcinoma.

NRG1 fusion positivity has gained interest as a treatment target in lung and pancreatic cancer, leading to the FDA approval of zenocutuzumab in December 2024.

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

First-line use of TTFields plus gemcitabine and nab-paclitaxel improved OS vs chemotherapy in unresectable, locally advanced pancreatic adenocarcinoma.

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.

Suneel Kamath, MD, shares insights on targeted therapies in pancreatic cancer after an X Takeover with OncLive during Pancreatic Cancer Awareness Month.

Suneel Kamath, MD, took to the OncLive X (Twitter) account during Pancreatic Cancer Awareness Month to share the importance of recognizing this disease.

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.

Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

Tanios Bekaii-Saab, MD, FACP, discusses the evolving treatment paradigm for BRCA1- and BRCA2-positive pancreatic cancer in the first-line setting.

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

MesoPher cell therapy led to a 2-year recurrence-free survival rate of 64% and low-grade AEs in resected pancreatic cancer following chemotherapy.

LODER plus chemotherapy led to responses and improved overall survival in unresectable, locally advanced pancreatic cancer.

The FDA has granted fast track designation to narmafotinib for the treatment of advanced pancreatic cancer.

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Ryan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.